Key Facts on theOngoing Ebola Outbreak in the Democratic Republic of Congo

The Ebola outbreak currently unfolding in the Democratic Republic of Congo risks becoming the deadliest on record, according to aid agencies.

By the end of May, just two weeks after the Congolese Ministry of Health announced the outbreak, it was already overwhelming the international response. At the epicenter, health workers and aid organizations were racing to contain the virus, yet the local infrastructure remained insufficient to curb its spread.

“Resource constraints are frequently inadequate,” said Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, in a social‑media post on Thursday as he commenced a visit to Congo. Over the weekend he traveled to Bunia, the outbreak’s epicenter, to express solidarity with frontline health‑care personnel.

As of Thursday, official figures from the Africa Centers for Disease Control and Prevention recorded at least 1,077 suspected cases and 246 suspected fatalities.

A significant complicating factor is that the pathogen involved—Bundibugyo—is relatively rare. Initial surveillance and testing failed to detect it promptly, delaying the response. Moreover, field diagnostic kits are limited, and no specific vaccine or treatment exists for this strain, complicating containment efforts.

Key aspects of the outbreak are outlined below.

Origin of the Outbreak

The precise onset remains unknown, but the first cases were identified in May within the Ituri Province of northeastern Democratic Republic of Congo.

Many residents of Ituri have been displaced by ongoing conflict, while migrant laborers are attracted to the area’s gold mines. The WHO notes that the region’s high population mobility could facilitate viral transmission.

Cases have been reported primarily in Ituri and North Kivu. On May 21, the rebel group M23, which controls large swathes of eastern Congo, announced an Ebola fatality in South Kivu province.

Travel Restrictions

Indeed, numerous countries have instituted screening protocols and tightened border controls.

The United States

The State Department has strongly urged U.S. citizens to avoid travel to Congo and its neighboring countries of South Sudan and Uganda. Travelers arriving from these nations are being redirected to four designated U.S. airports for health screening.

Furthermore, a 30‑day directive from the U.S. Centers for Disease Control and Prevention permits the denial of entry to foreign nationals who have been in Congo, Uganda, or South Sudan within the preceding 21 days.

On Thursday, U.S. officials announced plans for a 50‑bed quarantine facility in Kenya to accommodate Americans exposed to the virus, with adjoining isolation and biocontainment units for those who test positive or display symptoms during quarantine.

Earlier in May, the Trump administration arranged for an American physician exhibiting Ebola symptoms to be flown to a hospital in Germany. Six additional U.S. personnel were dispatched to Germany and the Czech Republic for monitoring.

Under prior administrations, infected health workers and other exposed Americans were typically repatriated for treatment at specialized U.S. medical facilities.

Canada

Canadian officials announced on Tuesday that travel and immigration processing for nationals of Congo, Uganda, and South Sudan will be suspended for 90 days, according to Canada’s national public broadcaster.

Uganda

In Uganda, health authorities have confirmed at least seven Ebola cases, including one fatality, the WHO reported on Monday. On Wednesday, Uganda closed its border with Congo amid rising concerns.

Contributions to the Relief Effort

In May, the U.S. State Department announced a $23 million allocation for protective equipment and related resources in Congo and Uganda, and pledged funding for up to 50 clinics, including associated frontline expenses.

However, public health experts and frontline workers note that a major obstacle to an effective international response is the limited involvement of the United States, which previously supported robust disease‑surveillance networks in the region.

The United States withdrew from the WHO in January, and last year the Trump administration dissolved the U.S. Agency for International Development, which had been instrumental in containing earlier outbreaks.

Currently on the ground, doctors are struggling to treat patients and contain the outbreak as aid workers from Médecins Sans Frontières rapidly set up isolation tents and disinfection stations near hospitals where deaths are occurring.

Family members often care for patients or collect bodies for burial without wearing protective equipment against the highly contagious disease.

Here are some other sources of support:

• The head of the United Nations humanitarian coordination agency announced the allocation of $60 million to support the response.

• The WHO disclosed that it had released $3.9 million from its contingency funds.

• The European Union and UNICEF announced the shipment of over 100 tons of equipment.

• The South African government has pledged $2.5 million.

• Congo’s government has allocated $20 million from its national budget to combat the outbreak, the health ministry reported.

Ebola is a disease caused by a group of related viruses known as orthoebolaviruses, first identified in 1976 in what are now South Sudan and the Democratic Republic of Congo, near the Ebola River. Fruit bats are believed to harbor these viruses asymptomatically.

Ebola outbreaks have predominantly occurred in sub‑Saharan Africa. In September of last year, Congolese health officials declared the nation’s 16th Ebola outbreak since 1976. The most extensive recorded epidemic began in 2014 across southeastern Guinea, Liberia, and Sierra Leone, persisting for two years.

Four of the six recognized Ebola virus species cause disease in humans and can be fatal.

Individuals infected with Ebola often initially develop so‑called dry symptoms—fever, aches, pains, and fatigue—before progressing to wet manifestations such as diarrhea, vomiting, and bleeding, according to the CDC.

Transmission occurs via direct contact with the bodily fluids of an infected, ill, or deceased person, as well as indirect contact with contaminated objects such as clothing, bedding, needles, or medical equipment.

The incubation period for the Bundibugyo strain ranges from two to 21 days, during which individuals typically are not infectious until symptoms appear. However, because early symptoms—such as fever and fatigue—mirror those of other diseases, including malaria, early detection can be challenging.

Vaccine Landscape

Vaccines and an antiviral medication have been approved for the Zaire species, which is the most prevalent, but no vaccine or specific therapy exists for the Bundibugyo strain.

The Bundibugyo virus was first identified in 2007 following an unexplained illness in the Bundibugyo District of Uganda, which borders Congo. A further outbreak was recorded in Congo in 2012.

Fatality rates during the two most recent Bundibugyo outbreaks have fluctuated between 30 % and 50 % of confirmed cases, the WHO reports.

According to Dr. Jean‑Jacques Muyembe, who heads Congo’s national biomedical research institute and is a pioneer in Ebola research, relatively little investigation has focused on this virus. Speaking at a briefing on Tuesday, he indicated that vaccine candidates are likely to be introduced in the coming days.

Brian Otieno contributed reporting from Nairobi, Kenya.

Source link